H.C. Wainwright Reiterates Buy Rating on Marker Therapeutics (MRKR) May 20, 2026 06:49AM
H.C. Wainwright Reiterates Buy Rating on Marker Therapeutics (MRKR) Mar 23, 2026 06:48AM
H.C. Wainwright Reiterates Buy Rating on Marker Therapeutics (MRKR) Jan 6, 2026 06:48AM
Marker Therapeutics (MRKR) PT Raised to $5.60 at Brookline Capital Markets Jan 5, 2026 06:43AM
H.C. Wainwright Reiterates Buy Rating on Marker Therapeutics (MRKR) Dec 8, 2025 08:30AM


Nov 14, 2025 07:49AM Marker Therapeutics (MRKR) Misses Q3 EPS by 12c
Oct 6, 2025 07:45AM Marker Therapeutics treats first patient with off-the-shelf T cell therapy
May 20, 2025 08:08AM Marker Therapeutics (MRKR) Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma
Feb 10, 2025 05:45PM Brookline Capital Markets Starts Marker Therapeutics (MRKR) at Buy
Jan 30, 2025 05:28PM Marker Therapeutics Announces Board Resignation
Dec 19, 2024 08:07AM Marker Therapeutics (MRKR) Provides a Clinical Update on MT-601 in Patients with Lymphoma
Dec 19, 2024 08:07AM Marker Therapeutics (MRKR) Announces $16.1 Million Private Placement
Dec 17, 2024 07:01AM Marker Therapeutics (MRKR) Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer
Nov 27, 2024 04:30PM Marker Therapeutics (MRKR) Files $300M Mixed Shelf
Nov 14, 2024 09:30PM Marker Therapeutics (MRKR) Misses Q3 EPS by 26c
Aug 12, 2024 07:01AM Marker Therapeutics (MRKR) Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma